From Bacterial Genomes to Novel Antibacterial Agents: Discovery, Characterization, and Antibacterial Activity of Compounds that Bind to HI0065 (YjeE) from Haemophilus influenzae

As part of a fully integrated and comprehensive strategy to discover novel antibacterial agents, NMR‐ and mass spectrometry‐based affinity selection screens were performed to identify compounds that bind to protein targets uniquely found in bacteria and encoded by genes essential for microbial viability. A biphenyl acid lead series emerged from an NMR‐based screen with the Haemophilus influenzae protein HI0065, a member of a family of probable ATP‐binding proteins found exclusively in eubacteria. The structure–activity relationships developed around the NMR‐derived biphenyl acid lead were consistent with on‐target antibacterial activity as the Staphylococcus aureus antibacterial activity of the series correlated extremely well with binding affinity to HI0065, while the correlation of binding affinity with B‐cell cytotoxicity was relatively poor. Although further studies are needed to conclusively establish the mode of action of the biphenyl series, these compounds represent novel leads that can serve as the basis for the development of novel antibacterial agents that appear to work via an unprecedented mechanism of action. Overall, these results support the genomics‐driven hypothesis that targeting bacterial essential gene products that are not present in eukaryotic cells can identify novel antibacterial agents.

[1]  David D. Anderson,et al.  Structure‐based Optimization of MurF Inhibitors , 2006, Chemical biology & drug design.

[2]  D. Chen,et al.  Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents. , 2005, Current medicinal chemistry.

[3]  J. García-Lara,et al.  Staphylococcus aureus: the search for novel targets. , 2005, Drug discovery today.

[4]  K. Johnson,et al.  PDF inhibitors: an emerging class of antibacterial drugs. , 2005, Current drug targets. Infectious disorders.

[5]  Eric D Brown,et al.  New targets and screening approaches in antimicrobial drug discovery. , 2005, Chemical reviews.

[6]  Cathy H. Wu,et al.  The Universal Protein Resource (UniProt) , 2004, Nucleic Acids Res..

[7]  E. Brown,et al.  Probing the active site of YjeE: a vital Escherichia coli protein of unknown function. , 2004, The Biochemical journal.

[8]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[9]  M. Etherton,et al.  Identification of antimicrobial targets using a comprehensive genomic approach. , 2004, Pharmacogenomics.

[10]  M. Schmid.  Seeing is believing: the impact of structural genomics on antimicrobial drug discovery , 2004, Nature Reviews Microbiology.

[11]  Mark E Schurdak,et al.  Affinity-based screening techniques for enhancing lead discovery. , 2004, Current opinion in drug discovery & development.

[12]  J. R. Huth,et al.  Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. , 2004, Analytical biochemistry.

[13]  James R. Brown,et al.  A Global Approach to Identify Novel Broad-Spectrum Antibacterial Targets among Proteins of Unknown Function , 2004, Journal of Molecular Microbiology and Biotechnology.

[14]  Jean M. Severin,et al.  Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. , 2004, Journal of medicinal chemistry.

[15]  David D. Anderson,et al.  Structure-activity relationships of novel potent MurF inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[16]  L. Rice.  Do we really need new anti-infective drugs? , 2003, Current opinion in pharmacology.

[17]  S. Ehrlich,et al.  Essential Bacillus subtilis genes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. D. Mills.  The role of genomics in antimicrobial discovery. , 2003, The Journal of antimicrobial chemotherapy.

[19]  Yvonne C. Martin,et al.  Ligand binding to domain-3 of human serum albumin: a chemometric analysis , 2003, J. Comput. Aided Mol. Des..

[20]  D. Livermore.  Bacterial resistance: origins, epidemiology, and impact. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  James R. Brown,et al.  Bioinformatics and the discovery of novel anti-microbial targets. , 2002, Current drug targets. Infectious disorders.

[22]  P. Hajduk,et al.  A Strategy for High-Throughput Assay Development Using Leads Derived from Nuclear Magnetic Resonance-Based Screening , 2002, Journal of biomolecular screening.

[23]  A. Boggs,et al.  A tour of recent patent applications addressing antibacterial resistance , 2002 .

[24]  N. Thanki,et al.  Crystal structure of the YjeE protein from Haemophilus influenzae: A putative Atpase involved in cell wall synthesis , 2002, Proteins.

[25]  B. Dougherty,et al.  Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. , 2002, Nucleic acids research.

[26]  R. Lunsford,et al.  Rational identification of new antibacterial drug targets that are essential for viability using a genomics-based approach. , 2002, Pharmacology & therapeutics.

[27]  J. Glass,et al.  Streptococcus pneumoniae as a genomics platform for broad-spectrum antibiotic discovery. , 2002, Current opinion in microbiology.

[28]  C. Lerner,et al.  Antibacterial drug discovery in the post-genomics era. , 2002, Current drug targets. Infectious disorders.

[29]  J. Mekalanos,et al.  A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Rosenberg,et al.  Exploiting genomics to discover new antibiotics. , 2001, Trends in microbiology.

[31]  P. Hajduk,et al.  Rational design of diflunisal analogues with reduced affinity for human serum albumin. , 2001, Journal of the American Chemical Society.

[32]  Elliot J. Lefkowitz,et al.  Genome of the Bacterium Streptococcus pneumoniae Strain R6 , 2001, Journal of bacteriology.

[33]  A. Gunasekera,et al.  Solution structure and function of a conserved protein SP14.3 encoded by an essential Streptococcus pneumoniae gene. , 2001, Journal of molecular biology.

[34]  M. Schmid.  Microbial genomics – new targets, new drugs , 2001, Expert opinion on therapeutic targets.

[35]  S. Salzberg,et al.  Complete Genome Sequence of a Virulent Isolate of Streptococcus pneumoniae , 2001, Science.

[36]  B Wieland,et al.  Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria. , 2001, Journal of molecular microbiology and biotechnology.

[37]  P. Warren,et al.  Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. , 2001, Drug discovery today.

[38]  J. Greene,et al.  Genetic Footprinting in Bacteria , 2001, Journal of bacteriology.

[39]  A. Fauci,et al.  Infectious diseases: considerations for the 21st century. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  H. Loferer.  Mining bacterial genomes for antimicrobial targets. , 2000, Molecular medicine today.

[41]  Renaldo Mendoza,et al.  NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups , 2000 .

[42]  J. Rosamond,et al.  Harnessing the power of the genome in the search for new antibiotics. , 2000, Science.

[43]  Michael Y. Galperin,et al.  Searching for drug targets in microbial genomes. , 1999, Current opinion in biotechnology.

[44]  K. Reich,et al.  Genome Scanning in Haemophilus influenzae for Identification of Essential Genes , 1999, Journal of bacteriology.

[45]  P. Hajduk,et al.  High-throughput nuclear magnetic resonance-based screening. , 1999, Journal of medicinal chemistry.

[46]  L. Kay,et al.  A robust and cost-effective method for the production of Val, Leu, Ile (δ1) methyl-protonated 15N-, 13C-, 2H-labeled proteins , 1999, Journal of biomolecular NMR.

[47]  G. Vovis,et al.  Genomics and Antimicrobial Drug Discovery , 1999, Antimicrobial Agents and Chemotherapy.

[48]  B. Rost.  Twilight zone of protein sequence alignments. , 1999, Protein engineering.

[49]  Thomas J. Raub,et al.  Determination of the Affinity of Drugs toward Serum Albumin by Measurement of the Quenching of the Intrinsic Tryptophan Fluorescence of the Protein , 1999, The Journal of pharmacy and pharmacology.

[50]  G. Church,et al.  Methods for generating precise deletions and insertions in the genome of wild-type Escherichia coli: application to open reading frame characterization , 1997, Journal of bacteriology.

[51]  R. Fleischmann,et al.  Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. , 1995, Science.

[52]  Thomas J. Raub,et al.  A General, Wide-Range Spectrofluorometric Method for Measuring the Site-Specific Affinities of Drugs toward Human Serum Albumin , 1995 .

[53]  J. Keeler,et al.  Minimizing Sensitivity Losses in Gradient-Selected 15N-1H HSQC Spectra of Proteins , 1994 .

[54]  V. Saudek,et al.  Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions , 1992, Journal of biomolecular NMR.

[55]  J. Walker,et al.  Distantly related sequences in the alpha‐ and beta‐subunits of ATP synthase, myosin, kinases and other ATP‐requiring enzymes and a common nucleotide binding fold. , 1982, The EMBO journal.

[56]  D. Bruns,et al.  A sensitive and precise isotopic assay of ATPase activity. , 1978, Analytical biochemistry.

[57]  K. Bush.  Antibacterial drug discovery in the 21st century. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[58]  D. Livermore.  The need for new antibiotics. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[59]  David J Payne,et al.  Genomic approaches to antibacterial discovery. , 2004, Methods in molecular biology.

[60]  P. Rosner,et al.  Strategic use of affinity-based mass spectrometry techniques in the drug discovery process. , 2002, Analytical chemistry.

[61]  D Steverding,et al.  A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. , 2000, Parasitology international.

[62]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .